QPS

The Quality Payments Scheme, forms part of the Community Pharmacy Contractual Framework, introduced on 1st December 2016. The original version of the scheme ran until 31st March 2018 and a total of £75 million was paid to community pharmacies for meeting the specified quality criteria.

The scheme was extended for the first six months of 2018/19, as part of interim arrangements prior to substantive negotiations being undertaken. The extended Scheme had a review point in June 2018 and funding of £37.5 million. In September 2018, a new Quality Payments Scheme was announced for the remainder of the 2018/19 financial year. The new scheme has funding of £37.5 million and a review point in February 2019. Changes to the Scheme are summarised inPSNC-Briefing-051.18-A-summary-of-the-second-Quality-Payments-Scheme-2018-19-v2

Gateway criteria

Domain
Criteria
Points
Patient Safety A written patient safety report (updated since 29 June 2018, i.e. the last review date or covering the last year if not previously claimed) at premises level available for inspection at review point covering analysis of incidents and incident patterns (taken from an ongoing log), evidence of sharing learning locally and nationally, and actions taken in response to national patient safety alerts; Demonstrably, the pharmacy contractor uploads any LASA incident reports to the NRLS and keeps a record for confirmation of this activity at the pharmacy premises or within any electronic reporting system used by the contractor. In the description of what happened in the NRLS report, the contractor must include the text ‘LASA’ as a unique identifier to facilitate future national learning.** NHS Improvement top combinations by likelihood and harm caused – propranolol and prednisolone, amlodipine and amitriptyline, carbamazepine and carbimazole, azathioprine and azithromycin, atenolol and allopurinol.  20
Patient Safety On the day of the review, 80% of all registered pharmacy professionals working at the pharmacy have satisfactorily completed the CPPE Risk Management training; and the pharmacy has available for inspection at the review point, at premises level, an example of a risk review that the pharmacy team at the premises have drawn up for a risk in that pharmacy that has been identified and prioritised with identified risk minimisation actions that the pharmacy team is taking.  20
Patient Safety On the day of the review the pharmacy must have completed the audit of non-steroidal anti-inflammatory drugs and gastro-protection for patients 65 or over, notified the patient’s GP where professional concerns were identified, share their anonymised data with NHS England and incorporated the learning of the audit into future practice. 20
Public Health On the day of the review the pharmacy is a Healthy Living Pharmacy level 1 (self-assessment) and;80% of staff working at the pharmacy (including pharmacy professionals) that provide healthcare advice to the public have successfully completed the CPPE children’s oral health training assessment. 15
Digital/Urgent Care On the day of the review, the pharmacy’s NHS 111 Directory of Services entry is up to date. 2.5
Clinical Effectiveness On the day of the review, the pharmacy can show evidence of asthma patients, for whom more than 6 short acting bronchodilator inhalers were dispensed without any corticosteroid inhaler within a 6 month period, have since 29th June 2018 (i.e. the last review date) been referred to an appropriate health care professional for an asthma review; and Can evidence that they have ensured that all children aged 5-15 years prescribed an inhaled corticosteroid for asthma have a spacer device where appropriate and have a personalised asthma action plan. Refer to an appropriate healthcare professional where this is not the case. 20
Workforce On the day of the review, 80% of all pharmacy staff working in patient facing roles are Dementia Friends (Alzheimer’s Society). 2.5
Total number of points: 100